About This Course
A few years ago, Denver decriminalized psilocybin mushrooms, beginning a far-reaching reform movement in psychedelic drugs. This wave placed pharmaceutical companies, who began to seek FDA approval of such drugs in direct opposition to activists who opposed commercialization. Oregon’s later legalization of psilocybin-assisted therapy clinics using products manufactured under state licenses only accelerated the spread and the conflict.
This CLE course will explain the patent protections available to licensees in a state “medical psychedelic” program as well as the degree to which pharmaceutical companies who have gained FDA approval for their medicine may restrict state-licensed actors and others in the market.